Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy

References

• Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012;13(12):1129-32
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy–revisited. Nature Rev Drug Discov 2011;10(8):591-600
   PubMed Web of Science ®Google Scholar
• Wood C. A vaccine for renal cancer. Lancet 2008;372(9648):1460-1
   Google Scholar
• Gulley JL, Madan RA, Tsang KY, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014;2(2):133-41
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175(9):6169-76
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19(5):1021-34
   PubMed Web of Science ®Google Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immuno 2010;10(8):580-93
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: ongoing clinical trials. Future oncol 2014;10(1):91-105
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014;257(1):56-71
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123(17):2625-35
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104(8):599-613
   PubMed Web of Science ®Google Scholar
• Tefit JN, Serra V. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev Vaccines 2011;10(8):1207-20
   PubMed Web of Science ®Google Scholar
• Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 2007;67(17):7945-7
   Google Scholar
• Sharma RK, Elpek KG, Yolcu ES, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009;69(10):4319-26
   PubMed Web of Science ®Google Scholar
• Sharma RK, Schabowsky RH, Srivastava AK, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010;70(10):3945-54
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? BioFactors 2013;39(4):355-67
   PubMed Web of Science ®Google Scholar
• Fisher DT, Chen Q, Appenheimer MM, et al. Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest 2006;35(3-4):251-77
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010;9(6):555-65
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011;23(2):286-92
   PubMed Web of Science ®Google Scholar
• Breart B, Lemaitre F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest 2008;118(4):1390-7
   Google Scholar
• Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011;17(14):4719-30
   PubMed Web of Science ®Google Scholar
• Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J Immunol 2010;184(8):4079-86
   Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014;20(6):607-15
   PubMed Web of Science ®Google Scholar
• Bobanga ID, Petrosiute A, Huang AY. Chemokines as Cancer Vaccine Adjuvants. Vaccines 2013;1(4):444-62
   PubMedGoogle Scholar
• BOOKS European Journal of Haematology. 1989;42(1):111-12
   Google Scholar
• Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity 2012;36(5):705-16
   PubMed Web of Science ®Google Scholar
• Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010;16(3):133-44
   PubMed Web of Science ®Google Scholar
• Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008;48:171-97
   PubMed Web of Science ®Google Scholar
• Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol 2004;25(6):315-22
   PubMed Web of Science ®Google Scholar
• Haribabu B, Verghese MW, Steeber DA, et al. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000;192(3):433-8
   PubMed Web of Science ®Google Scholar
• Okuno T, Yokomizo T, Hori T, et al. Leukotriene B4 receptor and the function of its helix 8. J Biol Chem 2005;280(37):32049-52
   Google Scholar
• Li RC, Haribabu B, Mathis SP, et al. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 2011;184(1):124-31
   Google Scholar
• Mathis S, Jala VR, Haribabu B. Role of leukotriene B4 receptors in rheumatoid arthritis. Autoimmun Rev 2007;7(1):12-17
   Google Scholar
• Mathis SP, Jala VR, Lee DM, Haribabu B. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol 2010;185(5):3049-56
   Google Scholar
• Sharma RK, Chheda Z, Jala VR, Haribabu B. Expression of leukotriene B(4) receptor-1 on CD8(+) T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol 2013;191(6):3462-70
   Google Scholar
• Spite M, Hellmann J, Tang Y, et al. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol 2011;187(4):1942-9
   Google Scholar
• Chou RC, Kim ND, Sadik CD, et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 2010;33(2):266-78
   PubMed Web of Science ®Google Scholar
• Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003;4(6):579-85
   PubMed Web of Science ®Google Scholar
• Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99(1):23-33
   PubMed Web of Science ®Google Scholar
• MartIn-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003;198(4):615-21
   PubMed Web of Science ®Google Scholar
• Del Prete A, Shao WH, Mitola S, et al. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 2007;109(2):626-31
   Google Scholar
• Dorner BG, Dorner MB, Zhou X, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009;31(5):823-33
   PubMed Web of Science ®Google Scholar
• Castellino F, Huang AY, Altan-Bonnet G, et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006;440(7086):890-5
   PubMed Web of Science ®Google Scholar
• Semmling V, Lukacs-Kornek V, Thaiss CA, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol 2010;11(4):313-20
   PubMed Web of Science ®Google Scholar
• Kaiser A, Donnadieu E, Abastado JP, et al.C chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol 2005;175(4):2349-56
   Google Scholar
• Goodarzi K, Goodarzi M, Tager AM, et al. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4(10):965-73
   PubMed Web of Science ®Google Scholar
• Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003;4(10):982-90
   PubMedGoogle Scholar
• Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol 2007;171(3):767-76
   PubMed Web of Science ®Google Scholar
• Fyhrquist N, Wolff H, Lauerma A, Alenius H. CD8+ T cell migration to the skin requires CD4+ help in a murine model of contact hypersensitivity. PLoS One 2012;7(8):e41038
   Google Scholar
• Perez de Lema G, Maier H, Franz TJ, et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005;16(12):3592-601
   Google Scholar
• Nanki T, Imai T, Nagasaka K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46(11):2878-83
   PubMed Web of Science ®Google Scholar
• Gunther C, Carballido-Perrig N, Kaesler S, et al. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. J Invest Dermatol 2012;132(3 Pt 1):626-34
   Google Scholar
• Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005;128(Pt 8):1747-63
   Google Scholar
• Helbig KJ, Ruszkiewicz A, Lanford RE, et al. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol 2009;83(2):836-46
   Google Scholar
• Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009;462(7272):510-13
   PubMed Web of Science ®Google Scholar
• Harris TH, Banigan EJ, Christian DA, et al. Generalized Levy walks and the role of chemokines in migration of effector CD8+ T cells. Nature 2012;486(7404):545-8
   PubMed Web of Science ®Google Scholar
• Abdi R, Means TK, Luster AD. Chemokines in islet allograft rejection. Diabetes Metab Res Rev 2003;19(3):186-90
   PubMed Web of Science ®Google Scholar
• Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005;80(3):378-84
   PubMed Web of Science ®Google Scholar
• Sato T, Thorlacius H, Johnston B, et al. Role for CXCR6 in recruitment of activated CD8+ lymphocytes to inflamed liver. J Immunol 2005;174(1):277-83
   Google Scholar
• Mrass P, Takano H, Ng LG, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 2006;203(12):2749-61
   PubMed Web of Science ®Google Scholar
• Mrass P, Kinjyo I, Ng LG, et al. CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity. Immunity 2008;29(6):971-85
   Google Scholar
• Boissonnas A, Fetler L, Zeelenberg IS, et al. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007;204(2):345-56
   PubMed Web of Science ®Google Scholar
• Deguine J, Breart B, Lemaitre F, et al. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity 2010;33(4):632-44
   PubMed Web of Science ®Google Scholar
• Salmon H, Franciszkiewicz K, Damotte D, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012;122(3):899-910
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39(4):782-95
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
   PubMed Web of Science ®Google Scholar
• Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010;70(21):8368-77
   PubMed Web of Science ®Google Scholar
• Lavergne E, Combadiere C, Iga M, et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004;173(6):3755-62
   Google Scholar
• Franciszkiewicz K, Le Floc’h A, Jalil A, et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 2009;69(15):6249-55
   Google Scholar
• Gough M, Crittenden M, Thanarajasingam U, et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 2005;174(9):5766-73
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gomez L, Lustgarten J, et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011;71(16):5455-66
   PubMed Web of Science ®Google Scholar
• Moran CJ, Arenberg DA, Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8(12):3803-12
   PubMed Web of Science ®Google Scholar
• Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7(2):285-9
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin YC, Mahalingam J, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012;72(5):1092-102
   PubMed Web of Science ®Google Scholar
• Molon B, Ugel S, Del Pozzo F, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011;208(10):1949-62
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002;217(1-2):12-22
   PubMed Web of Science ®Google Scholar
• Mullins IM, Slingluff CL, Lee JK, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004;64(21):7697-701
   Google Scholar
• Dengel LT, Norrod AG, Gregory BL, et al. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 2010;33(9):965-74
   Google Scholar
• Musha H, Ohtani H, Mizoi T, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005;116(6):949-56
   PubMed Web of Science ®Google Scholar
• Liu Y, Poon RT, Hughes J, et al. Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. Clin Immunol 2005;114(2):174-82
   Google Scholar
• Liu YQ, Poon RT, Hughes J, et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. World J Gastroenterol 2005;11(2):164-70
   Google Scholar
• Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int j Oncol 2005;26(1):41-7
   PubMed Web of Science ®Google Scholar
• Tang L, Hu HD, Hu P, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007;14(16):1226-34
   PubMed Web of Science ®Google Scholar
• Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005;35(5):1371-80
   Google Scholar
• Zeng Y, Huebener N, Fest S, et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 2007;67(5):2331-8
   Google Scholar
• Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008;181(5):3099-107
   PubMed Web of Science ®Google Scholar
• Maric M, Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res 1999;59(21):5549-53
   PubMed Web of Science ®Google Scholar
• Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996;7(13):1545-53
   PubMed Web of Science ®Google Scholar
• Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000;105(10):1383-93
   PubMed Web of Science ®Google Scholar
• Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178(3):1057-65
   Google Scholar
• Yokota Y, Inoue H, Matsumura Y, et al. Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems. Blood 2012;120(17):3444-54
   PubMed Web of Science ®Google Scholar
• Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003;300(5617):339-42
   PubMed Web of Science ®Google Scholar
• Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One 2013;8(9):e73145
   PubMed Web of Science ®Google Scholar
• Zhai Y, Wang Y, Wu Z, Kupiec-Weglinski JW. Defective alloreactive CD8 T cell function and memory response in allograft recipients in the absence of CD4 help. J Immunol 2007;179(7):4529-34
   Google Scholar
• Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008;180(5):3122-31
   PubMed Web of Science ®Google Scholar
• Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450(7171):903-7
   PubMed Web of Science ®Google Scholar
• Engelhardt JJ, Boldajipour B, Beemiller P, et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012;21(3):402-17
   PubMed Web of Science ®Google Scholar
• Boissonnas A, Licata F, Poupel L, et al. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia 2013;15(1):85-94
   Google Scholar
• Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014;4(5):522-6
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol 2013;3:231
   PubMedGoogle Scholar
• Hyakudomi M, Matsubara T, Hyakudomi R, et al. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008;15(6):1775-82
   Google Scholar
• Orinska Z, Bulanova E, Budagian V, et al. TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood 2005;106(3):978-87
   Google Scholar
• Calcinotto A, Grioni M, Jachetti E, et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012;188(6):2687-94
   PubMed Web of Science ®Google Scholar
• Guirnalda P, Wood L, Goenka R, et al. Interferon gamma-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with. Oncoimmunology 2013;2(8):e25752
   PubMed Web of Science ®Google Scholar
• Uekusa Y, Yu WG, Mukai T, et al. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res 2002;62(13):3751-8
   Google Scholar
• Mallick A, Barik S, Goswami KK, et al. Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS One 2013;8(1):e47434
   Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862-8
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11(18):6713-21
   PubMed Web of Science ®Google Scholar
• Dirkx AE, oude Egbrink MG, Castermans K, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006;20(6):621-30
   PubMed Web of Science ®Google Scholar
• Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 2014;63(3):259-71
   PubMedGoogle Scholar
• Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer immunol Res 2013;1(6):365-72
   PubMed Web of Science ®Google Scholar
• Kirk CJ, Hartigan-O’Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61(5):2062-70
   Google Scholar
• Clancy-Thompson E, King LK, Nunnley LD, et al. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 2013;1(5):332-9
   Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113(25):6392-402
   PubMed Web of Science ®Google Scholar
• Xu Y, Hyun YM, Lim K, et al. Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci USA 2014;111(17):6371-6
   PubMed Web of Science ®Google Scholar
• Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified t cells in solid tumors. Cancer Res 2014;74(18):5195-205
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Sampath P, et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012;14(12):1115-21
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011;19(4):650-7
   PubMed Web of Science ®Google Scholar
• Lin Y, Luo J, Zhu WE, et al. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model. Otolaryngol Head Neck Surg 2014;151(3):447-53
   Google Scholar
• Bazak R, Houri M, El Achy S, et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Tian Y, Li S, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014;35(7):2383-90
   PubMed Web of Science ®Google Scholar
• Garland SL. Are GPCRs still a source of new targets? J Biomol Screen 2013;18(9):947-66
   PubMedGoogle Scholar
• Allegretti M, Cesta MC, Garin A, Proudfoot AE. Current status of chemokine receptor inhibitors in development. Immunol Lett 2012;145(1-2):68-78
   PubMed Web of Science ®Google Scholar